Evidence map›Paper›PMID 34611470›Full record

ArticleThe World Allergy Organization journal2020

Efficacy predictors of omalizumab in Chinese patients with moderate-to-severe allergic asthma: Findings from a

Jing Li, Changzheng Wang, Chuntao Liu, Jian Kang, Lingfei Kong, Yijiang Huang, Shuang Liu, Mao Huang, Lu Wang, Robert Fogel and 3 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The World Allergy Organization journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01202903 (A 24-week, Phase III Randomized, Double-blind, Placebocontrolled, Parallel-group, Multicenter Study of Xolair®), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01202903 phase3completednot on this map

A 24-week, Phase III Randomized, Double-blind, Placebocontrolled, Parallel-group, Multicenter Study of Xolair® (Omalizumab) in Patients With Moderate to Severe Persistent Allergic Asthma Who Remain Not Adequately Controlled Despite GINA (2009) Step 4 Therapy

TypeinterventionalSponsorNovartis PharmaceuticalsRan2010 to 2013Enrolled616ConditionsPersistent Allergic AsthmaArmsOmalizumab, Placebo
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 3 countries.

Jing LiAllergy and Clinical Immunology Department, State Key Laboratory of Respiratory Disease, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Changzheng WangDepartment of Respiratory Disease, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
Chuntao LiuDepartment of Respiratory Disease, West China Hospital, Sichuan University, Sichuan, China.
Jian KangInstitute of Respiratory Disease, The First Hospital of China Medical University, Shenyang, China.
Lingfei KongInstitute of Respiratory Disease, The First Hospital of China Medical University, Shenyang, China.
Yijiang HuangDepartment of Respiratory Disease, Hainan General Hospital, Hainan Clinical Medicine Research Institution, Hainan, China.
Shuang LiuDepartment of Respiratory Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Mao HuangDepartment of Respiratory Disease, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Lu WangBeijing Novartis Pharma Co. Ltd., Beijing, China.
Robert FogelNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Xavier JaumontNovartis Pharma AG, Basel, Switzerland.
Jing YangBeijing Novartis Pharma Co. Ltd., Beijing, China.
Nanshan ZhongAllergy and Clinical Immunology Department, State Key Laboratory of Respiratory Disease, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
First Hospital of China Medical University · CNGuangzhou Medical University · CNNovartis (China) · CNArmy Medical University · CNCapital Medical University · CNHainan General Hospital · CNNanjing Medical University · CNNovartis (Switzerland) · CHNovartis (United States) · USWest China Hospital of Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOmalizumab has demonstrated efficacy as an add-on therapy in Chinese patients with moderate-to-severe allergic asthma. This

methodsA

resultsThis analysis included 608 patients (omalizumab, N = 306; placebo, N = 302). Improvements in forced expiratory volume in 1 s (FEV

conclusionsIn Chinese patients with moderate-to-severe allergic asthma, baseline IgE and allergen profile (number/PAR history) are potential predictors of treatment response to omalizumab.

trial registrationNCT01202903 (www.clinicaltrials.gov).

Indexed as

ACQ, Asthma Control QuestionnaireAllergicANCOVA, Analysis of covarianceAQLQ, Asthma Quality of Life QuestionnaireAsthmaChinaCMH, Cochran-Mantel-HaenszelEOS, EosinophilEosinophilsFAS, Full analysis setFCεR1, High affinity IgE binding receptor 1FEV1, Forced expiratory volume in 1 sGETE, Global Evaluation of Treatment EffectivenessICS, Inhaled corticosteroidIgE, Immunoglobulin-EIL-5, Interleukin-5Immunoglobulin ELABA, Long-acting β agonistLSM, Least squares meanLSM-TD, Least squares mean treatment differencesOmalizumabOMA, OmalizumabPAR, Perennial allergic rhinitisPBO, PlaceboPD, PharmacodynamicsPEF, Peak expiratory flowPK, PharmacokineticQoL, Quality of lifeRAST, Radio-allergosorbent testRMU, Rescue medication useSAR, Seasonal allergic rhinitisULOQ, Upper limit of quantification

Identifiers

PMID34611470
PMCPMC8461112
OpenAlexW3109667984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.